271 related articles for article (PubMed ID: 9548163)
21. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol.
Spona J; Feichtinger W; Kindermann C; Wünsch C; Brill K
Contraception; 1996 Nov; 54(5):299-304. PubMed ID: 8934064
[TBL] [Abstract][Full Text] [Related]
22. Etonogestrel implant (Implanon) for contraception.
Drug Ther Bull; 2001 Aug; 39(8):57-9. PubMed ID: 11526801
[TBL] [Abstract][Full Text] [Related]
23. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy.
Power J; French R; Cowan F
Cochrane Database Syst Rev; 2007 Jul; 2007(3):CD001326. PubMed ID: 17636668
[TBL] [Abstract][Full Text] [Related]
24. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
25. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
26. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
Sivin I; Lähteenmäki P; Mishell DR; Alvarez F; Diaz S; Ranta S; Grozinger C; Lacarra M; Brache V; Pavez M; Nash H; Stern J
Contraception; 1997 Nov; 56(5):317-21. PubMed ID: 9437561
[TBL] [Abstract][Full Text] [Related]
27. Endometrial effects of etonogestrel (Implanon) contraceptive implant.
Varma R; Mascarenhas L
Curr Opin Obstet Gynecol; 2001 Jun; 13(3):335-41. PubMed ID: 11396660
[TBL] [Abstract][Full Text] [Related]
28. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
[TBL] [Abstract][Full Text] [Related]
29. Endometrial angiogenic response in Norplant users.
Subakir SB; Hadisaputra W; Handoyo AE; Affandi B
Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
[TBL] [Abstract][Full Text] [Related]
30. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
Mulders TM; Dieben TO
Fertil Steril; 2001 May; 75(5):865-70. PubMed ID: 11334895
[TBL] [Abstract][Full Text] [Related]
31. A longitudinal study of changes in endometrial microvascular density in Norplant implant users.
Hickey M; Simbar M; Young L; Markham R; Russell P; Fraser IS
Contraception; 1999 Feb; 59(2):123-9. PubMed ID: 10361627
[TBL] [Abstract][Full Text] [Related]
32. Hormonal implants: contraception for a new century.
Darney PD
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1536-43. PubMed ID: 8178903
[TBL] [Abstract][Full Text] [Related]
33. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®.
Weisberg E; Croxatto HB; Findlay JK; Burger HG; Fraser IS
Contraception; 2011 Dec; 84(6):600-8. PubMed ID: 22078189
[TBL] [Abstract][Full Text] [Related]
34. Reduced endothelial cell migratory signal production by endometrial explants from women using Norplant contraception.
Subakir SB; Hadisaputra W; Siregar B; Irawati D; Santoso DI; Cornain S; Affandi B
Hum Reprod; 1995 Oct; 10(10):2579-83. PubMed ID: 8567774
[TBL] [Abstract][Full Text] [Related]
35. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
36. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon.
Affandi B
Contraception; 1998 Dec; 58(6 Suppl):99S-107S. PubMed ID: 10095980
[TBL] [Abstract][Full Text] [Related]
37. An integrated analysis of nonmenstrual adverse events with Implanon.
Urbancsek J
Contraception; 1998 Dec; 58(6 Suppl):109S-115S. PubMed ID: 10095981
[TBL] [Abstract][Full Text] [Related]
38. Immediate postpartum insertion of the norplant contraceptive device.
Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
[TBL] [Abstract][Full Text] [Related]
39. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
40. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
